Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRX NASDAQ:INMB NASDAQ:TNXP NASDAQ:VTYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.85-2.5%$5.48$2.20▼$7.19$210.37M1.51200,551 shs47,972 shsINMBINmune Bio$2.08-2.8%$2.24$1.71▼$11.64$55.30M1.04623,509 shs443,114 shsTNXPTonix Pharmaceuticals$24.00-2.9%$34.42$6.76▼$130.00$216.69M1.871.22 million shs1.17 million shsVTYXVentyx Biosciences$3.60+2.0%$2.67$0.78▼$3.91$251.72M1.011.20 million shs1.91 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-2.50%+1.92%+8.33%+7.04%+121.59%INMBINmune Bio-2.80%+3.48%+5.58%-20.15%-60.83%TNXPTonix Pharmaceuticals-2.91%-0.87%-13.36%-32.39%+83.91%VTYXVentyx Biosciences+1.98%+20.81%+39.53%+71.10%+70.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.85-2.5%$5.48$2.20▼$7.19$210.37M1.51200,551 shs47,972 shsINMBINmune Bio$2.08-2.8%$2.24$1.71▼$11.64$55.30M1.04623,509 shs443,114 shsTNXPTonix Pharmaceuticals$24.00-2.9%$34.42$6.76▼$130.00$216.69M1.871.22 million shs1.17 million shsVTYXVentyx Biosciences$3.60+2.0%$2.67$0.78▼$3.91$251.72M1.011.20 million shs1.91 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-2.50%+1.92%+8.33%+7.04%+121.59%INMBINmune Bio-2.80%+3.48%+5.58%-20.15%-60.83%TNXPTonix Pharmaceuticals-2.91%-0.87%-13.36%-32.39%+83.91%VTYXVentyx Biosciences+1.98%+20.81%+39.53%+71.10%+70.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 2.86Moderate Buy$11.0088.03% UpsideINMBINmune Bio 2.38Hold$18.50789.42% UpsideTNXPTonix Pharmaceuticals 2.33Hold$70.00191.67% UpsideVTYXVentyx Biosciences 2.00Hold$7.50108.33% UpsideCurrent Analyst Ratings BreakdownLatest INMB, VTYX, TNXP, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025EPRXEupraxia PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025INMBINmune BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TNXPTonix PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025VTYXVentyx BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.00(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AINMBINmune Bio$50K1,105.94N/AN/A$1.45 per share1.43TNXPTonix Pharmaceuticals$10.09M20.86N/AN/A$31.82 per share0.75VTYXVentyx BiosciencesN/AN/AN/AN/A$3.59 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-626.84%-118.31%11/6/2025 (Estimated)INMBINmune Bio-$42.08M-$2.48N/AN/AN/AN/A-120.62%-92.94%10/30/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)VTYXVentyx Biosciences-$135.12M-$1.68N/AN/AN/AN/A-48.89%-44.87%11/6/2025 (Estimated)Latest INMB, VTYX, TNXP, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025INMBINmune Bio-$0.31N/AN/AN/AN/AN/A8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 million8/7/2025Q2 2025INMBINmune Bio-$0.37-$0.34+$0.03-$1.05$0.00 millionN/A8/7/2025Q2 2025VTYXVentyx Biosciences-$0.45-$0.38+$0.07-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/AVTYXVentyx BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A8.728.72INMBINmune BioN/A4.204.20TNXPTonix PharmaceuticalsN/A7.537.22VTYXVentyx BiosciencesN/A19.1219.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AINMBINmune Bio12.72%TNXPTonix Pharmaceuticals82.26%VTYXVentyx Biosciences97.88%Insider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AINMBINmune Bio35.70%TNXPTonix Pharmaceuticals0.03%VTYXVentyx Biosciences14.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AINMBINmune Bio1026.59 million17.09 millionOptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableVTYXVentyx Biosciences3071.31 million60.98 millionOptionableINMB, VTYX, TNXP, and EPRX HeadlinesRecent News About These CompaniesClear Street Initiates Coverage of Ventyx Biosciences (VTYX) with Buy RecommendationOctober 2 at 5:09 AM | msn.comVentyx Biosciences initiated with a Buy at Clear StreetSeptember 30, 2025 | msn.comGoldman Sachs Group Inc. Has $682,000 Stock Position in Ventyx Biosciences, Inc. $VTYXSeptember 25, 2025 | marketbeat.comIeq Capital LLC Takes Position in Ventyx Biosciences, Inc. $VTYXSeptember 9, 2025 | marketbeat.comNuveen LLC Makes New $194,000 Investment in Ventyx Biosciences, Inc. $VTYXSeptember 8, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 157,070 Shares of Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comRedmile Group LLC Raises Holdings in Ventyx Biosciences, Inc. $VTYXSeptember 4, 2025 | marketbeat.comVentyx Biosciences to Participate in Three Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comH.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comVentyx Biosciences Reports Decreased Losses in 2025August 15, 2025 | msn.com3 Best Stocks to Buy Now, 8/11/2025, According to Top AnalystsAugust 11, 2025 | msn.comVentyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate ProgressAugust 9, 2025 | finance.yahoo.comVentyx (VTYX) Q2 Net Loss Drops 16%August 9, 2025 | theglobeandmail.comIs Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?July 22, 2025 | uk.finance.yahoo.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - NasdaqJuly 11, 2025 | nasdaq.comVentyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 10, 2025 | zacks.comAnalysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)June 24, 2025 | theglobeandmail.comVTYX - Ventyx Biosciences Inc News - MorningstarJune 24, 2025 | morningstar.comMVTYX - Ventyx Biosciences Inc Financials - MorningstarJune 24, 2025 | morningstar.comMVentyx Biosciences Insiders Placed Bullish Bets Worth US$1.26mJune 17, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINMB, VTYX, TNXP, and EPRX Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$5.85 -0.15 (-2.50%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$5.84 -0.01 (-0.26%) As of 10/3/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.INmune Bio NASDAQ:INMB$2.08 -0.06 (-2.80%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.07 -0.01 (-0.43%) As of 10/3/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Tonix Pharmaceuticals NASDAQ:TNXP$24.00 -0.72 (-2.91%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$24.00 +0.00 (+0.00%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.Ventyx Biosciences NASDAQ:VTYX$3.60 +0.07 (+1.98%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$3.59 -0.01 (-0.28%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? A Copper Catalyst: Why Freeport-McMoRan Is Positioned to Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
